For research and educational purposes only. Not medical advice.
Rapamycin Reference
Educational, not medical advice reference for Rapamycin: Longevity; regulatory status, evidence posture, source review, and schedule notes. Also known as Sir…
Reference summary
NIA Interventions Testing Program (Harrison 2009 Nature, Miller 2014 Aging Cell) showed reproducible mouse-lifespan extension on the order of 10-20 percent at typical doses, with up to roughly 23 percent in the highest-dose female arm of Miller 2014. Human data are limited to small rapalog immune-aging trials (Mannick 2014, 2018) and the PEARL Phase 2 trial (NCT04488601, completed; results pending) - all surrogate endpoints. No Phase 3 outcome trial in healthy adults exists.
Regulatory and posture
- Categories
- Longevity
- Aliases
- Sirolimus, Rapamune, Hyftor, mTOR inhibitor (small molecule, not a peptide)
- Evidence posture
- human - Off-label longevity use is investigational; no Phase 3 outcome trial in healthy adults.
- Regulatory status
- FDA-approved as Rapamune (1999) for prophylaxis of organ rejection in kidney transplantation, and as topical Hyftor (2022) for facial angiofibromas of tuberous sclerosis complex. Off-label longevity use is not FDA-approved and is investigational.
- Content review status
- label verified
Selected public sources
- DailyMed: Rapamune (sirolimus) prescribing information
- PubMed: Harrison et al. Nature 2009 - rapamycin extends mouse lifespan in NIA Interventions Testing Program (PMID 19587680)
- PubMed: Miller et al. Aging Cell 2014 - rapamycin-mediated lifespan increase in mice is dose and sex dependent (PMID 24341993)
- PubMed: Mannick et al. Sci Transl Med 2014 - mTOR inhibition and influenza vaccine response in older adults (PMID 25540326)
- PubMed: Mannick et al. Sci Transl Med 2018 - TORC1 inhibition reduces respiratory infections in older adults (PMID 29997249)